Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bu-Xue Yi-Mu particles for postpartum disease
ChiCTR1900028187Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Feb 2020
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of buxue yimu keli and yimucao in postpartum anemia, Lochia, postpartum abdominal pain and 2 more (2 arms), sponsored by Tongji Hospital. Primary endpoints: Hemoglobin, Lochia and 5 more. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
buxue yimu keliyimucao
03
Conditions
postpartum anemiaLochiapostpartum abdominal painsubinvolution of the uterusUrogynaecological Disorders
Beyond the preview
Go deeper on ChiCTR1900028187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028187.